explore -WSS

explore

author：entertainment 2025-10-01 15:40:13 - browse：4

A pharmacist hands a box of Wegovy — first opinion coverage from STAT — Bloomberg photo by George Frey

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit doses last May.

The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by enormous sales of Wegovy and Ozempic, the company’s sister drug for diabetes. The company also projected double-digit growth in sales and operating profit for 2024.

“I am pleased to state that we are now enabling more new U.S. patients to initiate treatment by more than doubling the amount of lower-dose strength Wegovy compared to previous months,” Novo CEO Lars Fruergaard Jørgensen said on a call with reporters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Novo: Oral version of Ozempic leads to 15% weight loss

WSS

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Ionis has late

Novo: Oral version of Ozempic leads to 15% weight loss

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Health tech startups drop sharply from 2021 highs

Biogen shutters digital health group, ends Apple study, in cost cutting move

Wikipedia

explore

explore

At least 13 dead in Texas as scorching temps continue

Paxlovid should be available without a positive Covid test

Novavax promises a turnaround & Lilly roils the obesity market

Why do women spend more than men on medical expenses?

Medicare details structure of new drug price negotiation program

FDA seeks to regulate lab

In Memoriam: Notable people who died in 2023

Shingles, which affected Dianne Feinstein, is on the rise

Peter Hotez and the public health issue of online harassment

Biogen nominates mother of director’s child to replace him on board

leisure time

Bispecific antibodies are next new thing in cancer immunotherapy

Xenotransplantation trials will require adjusting expectations, experts say

FDA approves first new drug developed for postpartum depression

Sudafed saga points to U.S. issues with evaluating older drugs

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Kaiser Permanente unions announce official strike date

explore

focus

explore

hotspot